 |
- Varenicline Boosts Long-term Quit Rate in Post-ACS Smokers: EVITA TCTMD
- Pfizer phase 4 study of Chantix/Champix in adolescent smokers fails to meet endpoint pharmabiz.com
- Study: Chantix reduces smoking one year after heart attack Infosurhoy
Full coverage
|